Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis.

2.50
Hdl Handle:
http://hdl.handle.net/10541/97938
Title:
Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis.
Authors:
Egan, J J; Stewart, J P; Hasleton, Philip S; Arrand, John R; Carroll, K B; Woodcock, A A
Abstract:
BACKGROUND: Cryptogenic fibrosing alveolitis (synonymous with idiopathic pulmonary fibrosis) is a clinically heterogeneous condition in which the precipitating factor is unclear. Both environmental and infective factors have been implicated. An association between Epstein-Barr virus (EBV) and cryptogenic fibrosing alveolitis was suggested over a decade ago by a study based on EBV serology, but the significance of this has been unclear. METHODS: Lung tissue obtained surgically from patients (n = 20) with cryptogenic fibrosing alveolitis was investigated for evidence of EBV replication and compared with lung tissue from 21 control patients. Fourteen of the 20 patients had received no specific therapy for cryptogenic fibrosing alveolitis at the time of biopsy. Monoclonal antibodies directed against the EBV viral antigens, EBV viral capsid antigen (VCA) and gp 340/220 antigen, which are expressed during the lytic phase of the EBV life cycle, were studied. RESULTS: Fourteen (70%) of the 20 patients with cryptogenic fibrosing alveolitis were positive for both EBV VCA and gp 340/220 compared with two (9%) of the 21 controls. In the patients with cryptogenic fibrosing alveolitis viral replication was localised to pulmonary epithelial cells using epithelial cell markers, and immunohistochemical analysis confirmed the staining to be within type II alveolar cells. CONCLUSIONS: This is the first report of in vivo EBV replication within epithelial cells of the lower respiratory tract in an immunocompetent human host. Furthermore, this suggests that EBV may be an immune trigger or contribute to lung injury in cryptogenic fibrosing alveolitis, thus offering a potential new avenue of treatment.
Affiliation:
North West Lung Centre, Wythenshawe Hospital, Manchester, UK.
Citation:
Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. 1995, 50 (12):1234-9 Thorax
Journal:
Thorax
Issue Date:
Dec-1995
URI:
http://hdl.handle.net/10541/97938
DOI:
10.1136/thx.50.12.1234
PubMed ID:
8553293
Type:
Article
Language:
en
ISSN:
0040-6376
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorEgan, J Jen
dc.contributor.authorStewart, J Pen
dc.contributor.authorHasleton, Philip Sen
dc.contributor.authorArrand, John Ren
dc.contributor.authorCarroll, K Ben
dc.contributor.authorWoodcock, A Aen
dc.date.accessioned2010-05-05T11:56:25Z-
dc.date.available2010-05-05T11:56:25Z-
dc.date.issued1995-12-
dc.identifier.citationEpstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. 1995, 50 (12):1234-9 Thoraxen
dc.identifier.issn0040-6376-
dc.identifier.pmid8553293-
dc.identifier.doi10.1136/thx.50.12.1234-
dc.identifier.urihttp://hdl.handle.net/10541/97938-
dc.description.abstractBACKGROUND: Cryptogenic fibrosing alveolitis (synonymous with idiopathic pulmonary fibrosis) is a clinically heterogeneous condition in which the precipitating factor is unclear. Both environmental and infective factors have been implicated. An association between Epstein-Barr virus (EBV) and cryptogenic fibrosing alveolitis was suggested over a decade ago by a study based on EBV serology, but the significance of this has been unclear. METHODS: Lung tissue obtained surgically from patients (n = 20) with cryptogenic fibrosing alveolitis was investigated for evidence of EBV replication and compared with lung tissue from 21 control patients. Fourteen of the 20 patients had received no specific therapy for cryptogenic fibrosing alveolitis at the time of biopsy. Monoclonal antibodies directed against the EBV viral antigens, EBV viral capsid antigen (VCA) and gp 340/220 antigen, which are expressed during the lytic phase of the EBV life cycle, were studied. RESULTS: Fourteen (70%) of the 20 patients with cryptogenic fibrosing alveolitis were positive for both EBV VCA and gp 340/220 compared with two (9%) of the 21 controls. In the patients with cryptogenic fibrosing alveolitis viral replication was localised to pulmonary epithelial cells using epithelial cell markers, and immunohistochemical analysis confirmed the staining to be within type II alveolar cells. CONCLUSIONS: This is the first report of in vivo EBV replication within epithelial cells of the lower respiratory tract in an immunocompetent human host. Furthermore, this suggests that EBV may be an immune trigger or contribute to lung injury in cryptogenic fibrosing alveolitis, thus offering a potential new avenue of treatment.en
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshAntigens, Viral-
dc.subject.meshBiological Markers-
dc.subject.meshCapsid Proteins-
dc.subject.meshEpithelium-
dc.subject.meshFemale-
dc.subject.meshHerpesvirus 4, Human-
dc.subject.meshHumans-
dc.subject.meshLung-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshPulmonary Fibrosis-
dc.subject.meshViral Matrix Proteins-
dc.subject.meshVirus Replication-
dc.titleEpstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis.en
dc.typeArticleen
dc.contributor.departmentNorth West Lung Centre, Wythenshawe Hospital, Manchester, UK.en
dc.identifier.journalThoraxen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.